Fernando Martinez, MD, MSChief, Division of Pulmonary and Critical Care
*Distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs).
*Compare novel antifibrotic therapies for IPF using clinical efficacy and safety data.
*Design a treatment plan for patients with IPF in consideration of the latest evidence on antifibrotic therapies and practice guidelines.
IPF is a chronic, progressive form of ILD that is characterized by lung fibrosis. Its incidence, prevalence, morbidity, and mortality are worsening. Therefore, it is becoming increasingly important for physicians to be adept at managing this condition from diagnosis through treatment selection and monitoring.
Using real-life clinical scenarios of patients with IPF, a leading expert will guide learners through evidence-based clinical decision-making based on recent practice guidelines and clinical data.
This event is sponsored by Clinical Care Solutions and is not sponsored by industry.